Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System (Globe Newswire)

FORT LAUDERDALE, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Pure-Vu® EVS System. The new Pure-Vu EVS System is intended to improve speed of set-up, enhance navigation capabilities in tortuous anatomy, build upon the excellent cleansing capabilities of the Pure-Vu system and enable physicians to rapidly overcome the challenges of poorly prepared colons during a colonoscopy.